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Abstract
Background: The relationship between breast cancer (BC) and thyroid disease (TD) is still controversial. The aim of
the study was to investigate the possible coexistence of TD in patients with newly diagnosed BC and its correlation
with BC clinical presentation with regard to menopausal status and stage of disease.
Methods: This is a retrospective cohort study of all patients treated for primary BC between 2014 and 2016 at the
Breast Unit of Trieste University Hospital. Clinical charts and reports were reviewed for coexisting thyroid disorders
(i.e. hyperthyroidism, hypothyroidism, benign TD, thyroid cancer, thyroid autoimmunity) and menopausal status at
the time of BC diagnosis. Biomolecular profile, stage, and grading of BC were also evaluated.
Results: A total of 786 women and 7 men were included in the study. Co-presence of TD was found in 161(20.3%)
cases: of these, 151(19.4%) patients presented benign TD and 10(1.3%) patients presented thyroid carcinoma.
Thyroid autoimmunity was found in 51(32%) patients. Regarding thyroid function, 88(55%) patients had
hypothyroidism, 19(12%) hyperthyroidism, and 54(33%) normal thyroid function. No statistically significant correlation
was found between age and TD (p = 0.16), although TD was more common in women aged ≥60 years. Women with
BC diagnosed at pre-menopausal age were more likely to have thyroid autoimmune diseases (45% vs. 29%, p = 0.05).
No association was detected among BC molecular profiles with either thyroid autoimmunity (p = 0.26) or altered
thyroid function (p = 0.63). High-grade BC was more frequent in women with hyperthyroidism (52.9%, p = 0.04), but
the grading was independent from the presence of thyroid autoimmune disease (p = 0.87). BC stage was related to
both thyroid autoimmunity (p = 0.04) and thyroid function (p < 0.001), with 55.2% of women affected by benign TD
presenting with stage I BC and more aggressive BCs found in hypothyroid patients.
Conclusions: According our study results, patients with primary BC present a greater incidence of autoimmunity
disorders, especially when diagnosed in the pre-menopausal setting. However, further prospective studies are required
to definitively prove causality.
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Background
Breast cancer (BC) is the most common malignancy in
women and the second most common cancer overall. Over
2 million new cases were diagnosed in 2018, accounting
for almost 25% of cancer cases among women [1]. Al-
though hereditary and genetic factors account for 5–10%
of BCs, nonhereditary factors are more commonly involved
in geographical and ethnic differences in incidence [2–6].
In this context, the relationship of BC with thyroid disease
(TD) has been widely investigated. However, data are still
controversial and, although almost every form of TD, in-
cluding autoimmunity disorders and thyroid cancer, has
been identified in association with BC, no convincing evi-
dence exists of a causal role for TD in BC [2–6].
A recent meta-analysis performed by Hardefeldt et al.
[7] found that patients with autoimmune thyroiditis pre-
sented an increased risk of BC (OR 2.92) and subgroup
analysis identified a significant association with both
anti-TPO and anti-TG thyroid antibodies. Although the
exact mechanism linking BC and TD has not been found
yet, several hypotheses have been postulated. The pos-
sible interactions between thyroid gland and breast
tissue may be based on the common property of both
epithelial tissues to concentrate iodine by means of a
sodium/iodine symporter (NIS), as well as on the
presence of TSH receptors in fatty tissue, which is
abundant in mammary glands [6]. Alternatively, since
estrogen receptors have been identified in abnormal
thyroid tissue cells, a reversal in the relationship with
BC acting as a trigger for thyroid dysfunction cannot
be excluded [3–6]. Additionally, some endocrine stim-
uli may exert a simultaneous action on both breast
and thyroid gland, determining the coincidence of
mammary and thyroid disorders [2–7].
Aim of this study was to evaluate the prevalence of TD
in a consecutive series of patients treated for primary BC
in order to assess any possible association in terms of clin-
ical presentation, management, and oncologic outcome.
Methods
Between January 2014 and December 2016, 823 patients
were treated for BC at the Breast Unit of Trieste Univer-
sity Hospital. Clinical data and information recorded
from patients charts as well as radiology and pathology
reports were retrospectively reviewed to assess for the
following inclusion criteria:
– pathological diagnosis of primary BC confirmed by
fine needle aspiration (FNA), core biopsy (CB), or
vacuum-assisted biopsy (VAB) with Mammotome®.
– presence of TD, including any form of benign
thyroid disease, thyroid cancer, thyroid
autoimmunity disorders, and/or altered thyroid
function (i.e. hypertyroidism, hypothyroidism).
Patients with recurrent BC, patients with metastatic
BC, and patients with histopathological diagnosis of
lymphoma or sarcoma of the breast were excluded from
the analysis.
According to these inclusion criteria, the study popu-
lation consisted of 793 patients.
Data analysis – breast Cancer
Variables routinely documented included patient age,
gender, menopausal status for the female sex, BC patho-
logical size, stage, grading and biological profile. In
agreement with NCCN Guidelines [8], menopausal sta-
tus was defined according to women age, with 60 years
as a cut-off value.
Immunohistochemical profiling of BC samples was
routinely performed as part of clinical care. According
to the American Joint Committee on Cancer (AJCC) sta-
ging system (7th Edition) [9] and the St. Gallen Inter-
national Expert Consensus [10], BC was classified into 4
subtypes:
– Luminal A: hormone-receptor (HR) positive, HER2
negative, low levels of Ki-67 protein;
– Luminal B: HR positive, with either positive or
negative HER2 and high levels of Ki-67 protein;
– HER2 type: HR negative, HER2 positive;
– Triple negative: HR negative, HER2 negative.
According to the above mentioned classification sys-
tems and current treatment guidelines, BC patients
underwent surgery (either breast conserving surgery or
mastectomy) and/or medical treatment (i.e. preopera-
tive/definitive chemotherapy and/or hormonal therapy).
Data analysis – thyroid disease
For every patient, the following variables were identified:
presence of benign TD, presence and histotype of thy-
roid carcinoma, presence of autoimmunity TD, thyroid
functional status.
Thyroid function was checked in every patient by means
of venous dosage of thyroid hormones (i.e. TSH, FT3,
FT4) and thyroid antibodies (i.e. anti-TPO and anti-TG).
Hyperthyroidism was defined as high synthesis and/or
secretion of thyroid hormones, determining suppressed
TSH values (< 0.40 μIU/mL). Hypothyroidism was de-
fined as reduced secretion of thyroid hormones, deter-
mining increased TSH values (> 4.00 μIU/mL).
Thyroiditis was defined by the presence of thyroid
antibodies and/or by means of ultrasound features and/
or on histological examination of surgical specimens.
Multinodular goiter was defined by the demonstration of
multiple follicular nodules on ultrasound examination
and/or on histological examination of surgical specimens.
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A thyroid ultrasound was performed in every patient
presenting with altered thyroid function. Thyroid scin-
tigraphy was indicated in case of hyperfunctioning dis-
ease, whereas FNA was carried out in patients with
thyroid nodules suspicious for malignancy. Definitive
histological examination was obtained in patients under-
going thyroidectomy.
Statistical analysis
Quantitative data were reported as mean, median, stand-
ard deviation and interquartile range. The qualitative
variables were expressed as absolute frequencies and
percentages. Chi-square test (or F-Fisher Exact test when
appropriate) and Proportion Test were used to assess as-
sociation between categorical variables:
– Correlation between menopausal status and thyroid
disease, autoimmune thyroid disease or thyroid
function;
– Correlation between breast cancer biological profile
and thyroid disease, autoimmune thyroid disease or
thyroid function;
– Correlation between breast cancer staging and
thyroid disease, autoimmune thyroid disease or
thyroid function;
– Correlation between breast cancer grading and
thyroid disease, autoimmune thyroid disease or
thyroid function.
Statistical analysis was performed using R (the R Foun-
dation for Statistical Computing; Version 3.0.3) software.
A p value less than 0.05 was considered statistically
significant.
Results
Between January 2014 and December 2016, 823 patients
were referred for BC at the Breast Unit of Trieste Uni-
versity Hospital. Of these, 793 patients were eligible for
the purposes of this study.
The cohort consisted of 786 (99%) women (mean age
66 ± 14 years), and 7 (1%) men (mean age 71 ± 12 years).
Among the female population, 30 patients presented bi-
lateral BC. Overall, 716 (87%) patients underwent breast
surgery and 107 (13%) patients were not considered for
surgery because of severe comorbidities and thus medic-
ally treated with hormonal therapy. BC molecular profile
was reported in 754 (95%) patients, while no information
were available in 39 (5%) cases because BC diagnosis
was made by on FNA cytology.
Information about thyroid function was recorded in
779 (98%) BC patients. Of these, 161 (21%, 160 women
and 1 man) presented both BC and TD, 151 (93.8%) of
them showed a benign TD and 10 (6.2%) presented ma-
lignant TD. Concerning data for thyroid cancer, mean
age at the time of diagnosis was 65 ± 13 years and tumor
subtypes were classified as follows: 8 papillary thyroid
carcinomas, 1 follicular thyroid carcinoma, and 1 medul-
lary thyroid carcinoma.
Among the 161 BC patients with concurrent TD, 88
(55%) patients had hypothyroidism, 19 (12%) patients
showed hyperthyroidism, and 54 (33%) patients had nor-
mal thyroid function.
Thyroid autoimmunity was identified in 51 (32%) pa-
tients out of 161 cases of BC with concurrent TD.
Table 1 shows the distribution of different TDs accord-
ing to thyroid function.
Correlation between menopausal status and TD,
autoimmune TD or thyroid function
Analysis was conducted on a cohort of 754 BC patients.
Patients with malignant TD (n = 10) and men (n = 7)
were excluded subgroup analysis.
At first, we investigated the correlation between meno-
pausal status and benign TD. Among pre-menopausal
women with BC, benign TD was found in 17% of pa-
tients. Similar percentage (21%) was found in BC women
aged > = 60 years (p = 0.16).
The analysis of correlation between menopausal status
and autoimmunity showed that autoimmune TD was di-
agnosed in 45% of pre-menopausal BC patients and in
29% of post-menopausal BC patients, with a borderline
significance at statistical analysis (p = 0.05). Moreover,
pre-menopausal BC women were more frequently affected
by autoimmune TD than post-menopausal BC ones, while
benign TD was generally much more common in post-
menopausal BC women (71% vs. 29%).
Evaluation of correlation between menopausal status
and thyroid function, showed no differences at statistical
analysis (p = 0.49).
Correlation between BC biological profile and TD,
autoimmune TD or thyroid function
Molecular profile of BC was determined on immunostain-
ing for 754 (95%) patients. Different BC molecular profiles
and their distribution according to menopausal status are
represented in Figs. 1, 2. BC subtypes TN and HER2+
were more frequently observed in pre-menopausal women
(p < 0.001). BC molecular profile was not associated with
benign TD (p = 0.85), nor with thyroid autoimmunity (p =
0.26) and not even with thyroid function (p = 0.63).
Correlation between BC staging and TD, autoimmune TD
or thyroid function
The analysis of a possible correlation between BC staging
and benign TD was possible in a subgroup of 136 cases
out of 151 (90%), with a median age at the time of diagno-
sis of 68 years.
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BC stage distribution related to benign TD is showed
in Table 2.
Different distribution of BC stage according to thyroid
function was recorded (p < 0.001). A major proportion of
stage I patients was observed among women with normal
thyroid function, whereas patients with higher BC stage
were more frequently affected by hypothyroidism (Table 3).
Analyzing the presence or absence of autoimmune
TD, no difference was found in distribution for stage 0, I
and II BC, while stage III BC was much more common
among women with autoimmune TD (14.6% vs. 4.5%,
p = 0,05). Data are reported in Table 4.
Correlation between BC grading and TD, autoimmune TD
or thyroid function
Figure 3 shows the correlation between BC grading and
benign TD.
Analysis of correlation between BC grading and thy-
roid function demonstrated that G3 carcinomas were
more represented in women with hyperthyroidism
(52.9%) than in those with hypothyroidism (38.6%) or
normal thyroid function (21.4%) (p = 0.04).
BC grading was not related to the presence or absence
of autoimmune TD (p = 0.87).
Discussion
BC and TD have a well known epidemiological impact
among the world population. Both pathologies have
greater incidence in women than in men and an increas-
ing number of cases has been diagnosed in recent years.
The possible correlation between BC and TD has been
widely discussed in literature, but data remain still con-
troversial [5, 7]. Some studies have shown an increased
prevalence of BC in patients with benign TD [4], but a
Table 1 Distribution of different thyroid disease divided according to thyroid function
Classification Diagnosis Number %
Hypothyroidism (88 CASES) Autoimmune 43 49%
Primary 30 34%
Multinodular goiter 10 11%
Caused by amiodarone 2 2%
Adenoma 1 1%
Papillary thyroid cancer 1 1%
After menopause 1 1%
Hyperthyroidism (19 CASES) Basedow disease 9 47%
Toxic multinodular goiter 8 42%
Caused by amiodarone 1 5%
Medullary thyroid cancer 1 5%
Plummer 0 0%
Euthyroidism (54 CASES) Multinodular goiter 24 44%
Thyroid nodules 21 39%
Papillary thyroid cancer 7 13%
Follicular thyroid cancer 1 2%
Endocrinopathologies not better specified 1 2%
Fig. 1 Breast cancer molecular profile
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clear relationship between hormonal status and serum
thyroid antibodies has not been demonstrated yet [5].
Several hypotheses have been postulated on the mech-
anism linking TD and BC. Some Authors showed that
the absorption and oxidation of iodine may play an im-
portant role in the development of BC, which is known
having a greater incidence in iodine-deficient geographic
areas [11–14]. Another possible interaction may be
based on the presence of a sodium/iodine symporter in
both the thyroid and breast tissue [15]. In this context,
Tazebay et al. [16] demonstrated that there is an in-
creased sodium/iodine symporter expression in thyroid
and breast cancer tissues compared to healthy breast tis-
sues. Consequently, this overexpression may play a role
in the development of targeted therapies and screening
programs for BC. The possible interaction between thy-
roid and mammary glands can also be explained by the
presence of TSH receptors in the adipose tissue of mam-
mary gland. In 2006, Conde et al. [17] showed that
pathological samples of non-invasive BCs there were
many more thyroid receptors α (TR-α) than in patho-
logical samples of invasive BCs. Furthermore, Jerzak
et al. [18] found that BC patients overexpressing this
type of receptors showed a better outcome.
The present retrospective analysis aimed to assess the
correlation between TD and BC with particular regard
to different variables, namely menopausal status, BC
molecular profile, and BC staging and grading. Accord-
ing to the results of this study, no differences were ob-
served between pre- and post-menopausal women in
terms of benign TD and/or altered thyroid functional
status.
Differences was observed regarding autoimmune thy-
roiditis, with pre-menopausal BC patients being more
frequently affected by this pathology than post-
menopausal BC patients (45% vs. 29%, p = 0.05). Similar
results have been recently published by Chiappa et al.
[19], who described an association between chronic
autoimmune thyroiditis and BC diagnosed in pre-
menopausal state. However, these results may not be
completely comparable, since for Chiappa and colleagues
post-menopause was defined as women aged > = 45 years
instead of 60 years. Anyway, several other studies have
shown an association between BC and autoimmune TD
[20], although the underlying reasons for this correlation
are still unclear. In 2001, Gogas et al. [21] demonstrated
a higher frequency of autoimmune thyroiditis in subjects
with more advanced BC, therefore suggesting a possible
correlation between thyroid autoimmunity and a worse
BC prognosis. On the other hand, Smith et al. [22] pub-
lished completely different data, giving evidence of a bet-
ter prognosis in patients suffering from autoimmune
TD. Giustarini et al. [23] evaluated thyroid autoimmun-
ity in patients with malignant and benign breast diseases
before surgery and observed a significantly higher pres-
ence of thyroid antibodies in BC patients compared to
patients suffering from benign breast disease. Recently,
Muller et al. [24] found no difference in terms of 10-
year survival for BC patients with or without thyroid
antibodies at blood tests analysis.
In the present series, the well-known aggressive TN
and Her2 positive BC subtypes were more frequently ob-
served in pre-menopausal women (p < 0.001), although
no correlation was found with thyroid autoimmunity
(p = 0.26). When considering thyroid functional status,
Fig. 2 Different breast cancer molecular profiles and their distribution according to menopausal status
Table 2 Distribution of Breast cancer stage in women with
benign thyroid disease
TNM Stage N° %
Stage 0 15 11.0%
Stage I 75 55.2%
Stage II 35 25.7%
Stage III 11 8.1%
Total 136 100.0%
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in the current study 55% of patients presented with
hypothyroidism, 12% with hyperthyroidism and 33%
with normal thyroid function. At statistical analysis, no
significant correlation was found with the menopausal
status (p = 0.49). Regarding the possible relationship be-
tween BC staging and the presence of benign TD, this
study found that patients with normal thyroid function
presented predominantly AJCC stage I disease (67.5%),
whereas patients with hypothyroidism presented more
frequently AJCC stage II-III disease (12.2%). This could
indicate that a reduced thyroid function might predis-
pose to develop a more advanced stage of BC, while a
condition of euthyroidism seems to correlate with lower
BC stage. In this context, Sogaard et al. [25], in a case-
control epidemiological study conducted on a large
cohort of Danish women, showed an increased risk of
BC in women with hyperthyroidism and a slightly in-
creased risk of BC in women with hypothyroidism. On
the other hand, Angelousi et al. [26] reported in their
study a lower incidence of lymph node metastasis in
hypothyroid patients suffering from BC, thus suggesting
that hypothyroidism might represent a protective factor
in BC outcome.
As far as the correlation between BC stage and the
presence of autoimmune TD is concerned, the results of
this study showed that there were no significant differ-
ences in the number of patients with autoimmune and
non-autoimmune TD in BC stage 0, I and II. Conversely,
BC stage III disease was significantly more common
among women with autoimmune TD (14.6% vs. 4.5%,
p = 0,05). This result is surprisingly in contrast with
literature data, because several Authors have reported a
higher prevalence of thyroid peroxidase antibodies
(TPO-Abs) in BC patients, underlining their potentially
protective role in terms of oncologic prognosis [27, 28].
Nevertheless, this result may reinforce the hypothesis
that a reduced thyroid function, present in most cases of
autoimmune thyroiditis, could predispose to develop
more advanced stage of BC.
Regarding the concomitant occurrence of BC and thy-
roid cancer, the present series recorded only 10(1.3%)
cases, all women and with a greater predominance of
papillary thyroid carcinoma, reflecting the high epi-
demiological frequency of this type of thyroid cancer.
Last but not least, when assessing for a possible correl-
ation between BC and benign TD, the present analysis
showed that the vast majority (56.3%) of women with
benign TD had G2 BC while G3 carcinomas were more
represented among women with hyperthyroidism
(52.9%), suggesting that an increased thyroid function
may correlate with a higher grading of BC. Lastly, statis-
tical analysis showed that BC grading is independent
from the presence of autoimmune TD.
Conclusions
The present study has a number of limitation. Being a
single-center experience based on retrospective non-
randomized analysis, the possibility of generalizing the
results is potentially limited. Additionally, the sample
size is not very large and the observation period might
not be long enough. However, the study managed to
confirm that there is a relationship between BC and TD,
Table 4 Distribution of breast cancer stage according to the presence or absence of autoimmune thyroid disease
Stage Absence of autoimmune thyroid disease Autoimmune thyroid disease
Stage 0 10 (11.4%) 5 (10.4%)
Stage I 50 (56.8%) 25 (52.1%)
Stage II 24 (27.3%) 11 (22.9%)
Stage III 4 (4.5%) 7 (14.6%)
Total 88 48
Breast cancer stage III was more common among women with autoimmune thyroid disease (14.6% vs 4.5%, p = 0,05, Proportion Test)
Table 3 Breast cancer stage related to thyroid function
Stage Hypothyroidism Hyperthyroidism Euthyroidism
Stage 0 10 (12.2%) 2 (14.3%) 3 (7.5%)
Stage I 42 (51.2%) 6 (42.9%) 27 (67.5%)
Stage II 20 (24.4%) 5 (35.7%) 10 (25.0%)
Stage III 10 (12.2%) 1 (7.1%) 0 (0.0%)
Total 82 14 40
Different distribution of breast cancer stage according to thyroid function (p < 0–001, Fisher Test)
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although further studies with prospective analyses and
extended follow-up are required in order to elucidate
the nature of this relationship. Future research might in-
vestigate the precise pathological mechanisms that cor-
relate the two pathologies also by checking the presence
of estrogen and progesterone receptors on histologic
specimens of thyroid carcinomas in order to possibly
identify a subgroup of patients with higher risk of devel-
oping BC.
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